PPT-Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety
Author : sherrill-nordquist | Published Date : 2018-11-21
Ritonavir Carey Hwang 1 Dirk Schürmann 2 Christian Sobotha 2 Marta Boffito 3 Heather Sevinsky 1 Neelanjana Ray 1 Palanikumar Ravindran 1 Hong Xiao 1 Mark
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Second-Generation HIV-1 Maturation Inhi..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety: Transcript
Ritonavir Carey Hwang 1 Dirk Schürmann 2 Christian Sobotha 2 Marta Boffito 3 Heather Sevinsky 1 Neelanjana Ray 1 Palanikumar Ravindran 1 Hong Xiao 1 Mark Krystal. sex. Stefan . Esser1, Marina Arendt2. , Robert Jablonka1, . Christina Schulze1, Volker Holzendorf3, . Norbert . H. Brockmeyer4, Karl-Heinz Jöckel2. , Raimund . Erbel2, Nico Reinsch5 . on . behalf of HIV HEART Study Group and Heinz Nixdorf Recall Investigative . (MK-1439; DOR). . NNRTI. Merck. Filed with USFDA. Cabotegravir-LA. (GSK-744; CAB). For . PrEP. INI. ViiV. Topical microbicide. Oral. Long-acting (LA) parenteral. 1. Fostemsavir. (BMS-663068). Prodrug of . (GSK-744; CAB). For . PrEP. INI. ViiV. Topical microbicide. Oral. Long-acting (LA) parenteral. 1. Fostemsavir. (BMS-663068). Prodrug of . BMS-626529. Attachment inhibitor. BMS . ViiV. MK-8591 (. EFdA. Joseph J. Eron Jr, MD Professor of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina Antiretroviral Therapy New Drugs: The Only Thing That Stays the Same is Change FORMATTED: 04/19/2016 Joseph J. Eron, Jr, MD Professor of Medicine and Epidemiology The University of North Carolina at Chapel Hill Chapel Hill, North Carolina Future Directions: Investigational Approaches to Antiretroviral Therapy JAKARTA (CAPITAL CITY OF INDONESIA). DENGUE CASES IN INDONESIA. DENGUE CASES IN INDONESIA. Antiviral to dengue VIRUS (DENV). Antiviral to dengue VIRUS (DENV). ANIMAL MODEL. TITER OF DENV FROM MICE SERA. use many of the host cell’s biochemical mechanisms and products to sustain their viability. A mature virus(virion) can exist outside a host cell and still retain its infective properties.. . 3. the virus. Krystyna Naumenko. 1*. , . Polina. Zaremba. 1. , . Svitlana. Zagorodnya. 1. , . Serhii. Siryi. 2. , . Yaroslav. . Borodkin. 2. , . Yurii. Shermolovych. 2. 1. Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Acad. . HIV1 and slower to progress to AIDS.. Most cases are due to type1.. Modes of transmission. 1-sexual.. 2- perinatal.. 3-parenteral(occupational and intravenous drug injection).. 4- blood transfusion.. enzyme inhibitors (ACE inhibitors). inhibit the conversion of angiotensin I to angiotensin II.. The. . main . indications of ACE inhibitors are shown below.. Heart Failure. ACE inhibitors are used in all grades of heart failure, . C. Dr . Manica. . Balasegaram. , WIPO Seminar, 2014. Generic competition needed. MSF Access Campaign. HIV. :. early successes not sustained. 1. st. line ARVs: no product patent protection in India until 2005 = rock bottom prices. . The University of North Carolina at Chapel Hill. Chapel Hill, North Carolina. Future Directions: Investigational Approaches to Antiretroviral Therapy. Washington, DC: . August . 24, . 2016. . Future Directions: . Rama . Karadsheh. . 1. , and Megan . Meuser. . 1. , Simon . Cocklin. . 1*. . 1. Department of Biochemistry, Drexel University, 245 North 25. th. Street, Philadelphia, Pennsylvania, USA. *. Corresponding author: sc349@drexel.edu. Background. Seasonal influenza is estimated to cause approximately 300,000 to 650,000 deaths worldwide annually. Currently, recommended antiviral agents for influenza (. oseltamivir. ) have not been studied in placebo controlled randomised trials to demonstrate survival benefit in hospitalized patients with influenza.
Download Document
Here is the link to download the presentation.
"Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
